What TB-500 Is

Thymosin beta-4 (TB-4) is a 43-amino-acid protein first isolated from the thymus gland in the 1960s, but subsequent research found it everywhere: platelets, wound fluid, developing tissue, regenerating muscle. It is among the most conserved peptides across species, suggesting an ancient and fundamental role in tissue repair.

TB-500 is a 7-amino-acid fragment (positions 17–23, sequence LKKTETQ) of that parent molecule — the specific region responsible for actin binding and cell migration (~800 Da vs ~4,900 Da for full-length TB-4).

The naming problem: Most vendors selling TB-500 are actually selling full-length TB-4. Doping control analysis confirmed vials labeled TB-500 contained the full 43-amino-acid protein. Check the Certificate of Analysis: if molecular weight is ~4,900 Da, you have TB-4 regardless of label.

How TB-500 Works

Enables rapid cell migration

The LKKTETQ sequence binds G-actin monomers, preventing premature assembly into filaments (actin sequestration). This creates a reserve pool that cells can rapidly deploy when they need to move, divide, or reorganize. The practical result: fibroblasts migrate efficiently into injured tendons, endothelial cells extend into damaged zones to form new blood vessels, and keratinocytes advance across wound surfaces.

Builds new blood vessels

Fragment 17–23 specifically promotes blood vessel formation. BPC-157 upregulates VEGF (the signal to build vessels); TB-500 enables the endothelial cells to physically move and organize into functional capillaries. The two address different parts of the same process.

Reduces excessive scarring

This effect comes from TB-4, not the TB-500 fragment. Anti-fibrotic activity belongs to Ac-SDKP, a 4-amino-acid fragment (positions 1–4) released when TB-4 is enzymatically processed. TB-500 does not contain the Ac-SDKP sequence and does not produce this anti-fibrotic effect. If scar reduction is a primary goal, TB-4 (the full molecule) is what the evidence supports.

Shifts immune cells toward repair

TB-4 promotes the shift from inflammatory M1 toward reparative M2 macrophages. This has been studied with full-length TB-4, not the isolated 17–23 fragment.

Applications

Tendon and ligament healing

Addresses stalled healing from failed cell migration and organization. What to expect: weeks 1–2 morning stiffness and first-step pain decrease; weeks 3–4 range of motion improves; weeks 5–8 eccentric loading tolerance increases.

Wound healing

Accelerates wound closure: keratinocytes migrate faster, endothelial cells form new vasculature, fibroblasts deposit organized collagen. A trial of 72 patients with chronic venous ulcers found ~25% complete closure at 3 months using 0.03% thymosin beta-4 gel.

Corneal healing (most advanced human data)

The SEER-1 Phase 3 trial enrolled 18 patients with neurotrophic keratopathy: 60% (6/10) receiving thymosin beta-4 achieved complete corneal healing vs 12.5% (1/8) on placebo; at Day 43, 50% of treated maintained complete healing vs 0% placebo (p=0.0359).

Cardiac repair (preclinical)

In mouse models of myocardial ischemia, TB-4 activated signaling pathways that promote cardiac cell migration and survival (integrin-linked kinase pathway). Preclinical only.

Dosing

Common approach: 2 mg twice weekly (Mon/Thu) for the first 4 weeks; titrate up to 3–4× weekly if response is slow; taper to 2–4 mg/week after week 4. Cycle length 6–8 weeks, repeatable after a 4–8 week break.

Route: SC or IM both work; IM may be preferred for deeper musculoskeletal injuries. Inject near the injury site when possible — local injection provides a higher first-pass concentration before systemic dilution.

Why not daily: TB-500 works by mass-action, binding G-actin monomers one-to-one. Once reserves are established, the effect persists for days even though the peptide clears in hours (half-life 0.5–2.1 h IV). This is why 2–4 mg doses 2–3×/week outperform smaller daily doses.

Side Effects and Safety

Phase 1 human data: 84 healthy volunteers tolerated recombinant TB-4 at doses up to 25 µg/kg daily for 10 days with no serious adverse events. Note this used recombinant TB-4, not synthetic TB-500.

Contraindications (absolute): active cancer or malignancy within 2 years; pregnancy or breastfeeding; proliferative retinopathy; surgery planned or recent (<2 weeks). Relative: concurrent corticosteroid use, severe cardiovascular disease, active autoimmune conditions, therapeutic anticoagulation.

Stacking with BPC-157

Wolverine Stack protocol: BPC-157 500–750 mcg daily SC near injury + TB-500 2–4 mg 2× weekly SC near injury. Cycle 6–8 weeks (TB-500), 8–12 weeks (BPC-157). See BPC-157 + TB-500 Protocol Guide.